Differential neutralizing antibody responses to varicella-zoster virus glycoproteins B and E following naked DNA immunization.
The only available vaccine against varicella-zoster virus (VZV) consists of the VZV-Oka attenuated but persistent virus strain. Development of a safer, subunit vaccine is therefore desirable. In this prospect, nucleic acid vaccines, expressing truncated forms of VZV glycoproteins B (recgB) and E (recgE) from which the anchor and the cytoplasmic domains were deleted, were used to immunize mice. Vaccination with recgB encoding plasmid elicited a strong and specific humoral immune response. Total IgG and neutralizing titres were comparable to those previously obtained by vaccination with purified and adjuvanted native recgB. In contrast, mice immunization with recgE encoding plasmid only induced a very weak immune response whereas we previously showed that vaccination with adjuvanted native or denatured recgE protein led to high neutralizing titres. The weakness of the immune response induced by recgE-encoding plasmid depended neither on the deletion of the anchor domain in the gE gene nor on the animal model. Analysis of antibody isotypes produced by plasmid immunizations revealed a response slightly dominated by IgG2a. Taken together, the data indicate that a VZV subunit vaccine based on adjuvanted recombinant glycoprotein E is more promising than a nucleic acid-based vaccine strategy. As regards recgB, both vaccination approaches might be appropriate.
Massaer
M
M
Applied Genetics, Université Libre de Bruxelles, Gosselies, Belgium.
Haumont
M
M
Garcia
L
L
Mazzu
L
L
Bollen
A
A
Jacobs
P
P
Jacquet
A
A
D000818:Animals; D000914:Antibodies, Viral / Q000276:immunology*; D016466:CHO Cells; D006224:Cricetinae; D004195:Disease Models, Animal; D015870:Gene Expression; D005818:Genetic Engineering; D014645:Herpesvirus 3, Human / Q000276:immunology*; D007074:Immunoglobulin G / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D009500:Neutralization Tests; D010957:Plasmids; D014611:Vaccination; D019444:Vaccines, DNA / Q000276:immunology*; D014759:Viral Envelope Proteins / Q000235:genetics / Q000276:immunology*; D014765:Viral Vaccines / Q000276:immunology*
D000914:Antibodies, Viral; D007074:Immunoglobulin G; D019444:Vaccines, DNA; D014759:Viral Envelope Proteins; D014765:Viral Vaccines; C090198:glycoprotein B, varicella-zoster virus; C056913:glycoprotein E, varicella-zoster virus